Literature DB >> 9085442

Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis.

A Spadaro1, E Taccari, V Riccieri, F Sensi, A Sili Scavalli, A Zoppini.   

Abstract

We studied the effect of a 6-month treatment with low-dose MTX in 22 RA patients, with the purpose of investigating the relationship of sIL-2R and IL-6 serum changes with those of class specific RFs. The patients with RA had higher serum levels of sIL-2R (p < 0.0001), and IL-6 (p < 0.0005) than healthy volunteers. We found that the levels of IgM-RF (p < 0.0004), IgA-RF (p < 0.002), IgG-RF (p < 0.025), sIL-2R (p < 0.017) and IL-6 (p < 0.044) as well as the main clinical and laboratory variables, were significantly reduced in RA patients treated with low dose MTX for six months. The changes from baseline of IgM-RF correlated with those of IL-6 (p < 0.023), suggesting that MTX may affect IL-6 and IgM-RF production in part by a common mechanism. In conclusion our results show that there is a relationship between IL-6 and IgM-RF changes from baseline during MTX therapy, but the hypothesis of a link between the effects of this drug on cytokine network and RF production needs further investigation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9085442

Source DB:  PubMed          Journal:  Rev Rhum Engl Ed        ISSN: 1169-8446


  5 in total

1.  Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab.

Authors:  A Kuuliala; R Nissinen; H Kautiainen; H Repo; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2005-06-07       Impact factor: 19.103

2.  Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.

Authors:  Tânia Silvia Fröde; Patrícia Tenconi; Marilei Reynaud Debiasi; Yara Santos Medeiros
Journal:  Mediators Inflamm       Date:  2002-12       Impact factor: 4.711

3.  Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.

Authors:  Miguel Perez-Aso; M Carmen Montesinos; Aránzazu Mediero; Tuere Wilder; Peter H Schafer; Bruce Cronstein
Journal:  Arthritis Res Ther       Date:  2015-09-15       Impact factor: 5.156

Review 4.  Molecular mechanism of action and pharmacokinetic properties of methotrexate.

Authors:  V Maksimovic; Z Pavlovic-Popovic; S Vukmirovic; J Cvejic; A Mooranian; H Al-Salami; M Mikov; S Golocorbin-Kon
Journal:  Mol Biol Rep       Date:  2020-05-15       Impact factor: 2.316

Review 5.  Molecular action of methotrexate in inflammatory diseases.

Authors:  Edwin S L Chan; Bruce N Cronstein
Journal:  Arthritis Res       Date:  2002-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.